ProMIS Neurosciences is expected to report a Q2 2026 loss of $1.38 per share on zero revenue, with its stock currently trading near $14.72 against an average analyst price target of $40.00.
The primary focus for investors is clinical execution, specifically regarding progress for the lead Alzheimer’s therapeutic candidate, PMN310.
Sentiment remains bolstered by late-July interim Phase 1b data showing a favorable safety profile with no reported cases of brain swelling (ARIA-E). Management is expected to provide further updates on biomarker trends and the company’s cash runway to support operations through the 12-month topline readout in early 2027.